Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

WHWK - Whitehawk Therapeutics, Inc.... | Finranks

Home

/

WHWK

W

Whitehawk Therapeutics, Inc. (WHWK)

NCM – Цена в реальном времени. Валюта: USD

4.72

+0.05 (1.07%)

При закрытии: Aug 12, 2026, 3:59 PM EDT

4.71

0.00 (0.00%)

После закрытия: Aug 12, 2026, 4:01 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026 Cash, cash equivalents and short-term investments of $190.0 million as of June 30, 2026, anticipated to fund operations into 2H 2028 MORRISTOWN, N.J., Aug. 6, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced financial results for the quarter ended June 30, 2026, and provided recent corporate highlights.

Видео

No Data

There is no data to display

Пресс-релизы

Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026 Cash, cash equivalents and short-term investments of $190.0 million as of June 30, 2026, anticipated to fund operations into 2H 2028 MORRISTOWN, N.J., Aug. 6, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced financial results for the quarter ended June 30, 2026, and provided recent corporate highlights.